Therapeutic strategies targeting Caspase-3 cleavage of SPTBN1 or modulating nuclear translocation of SPTBN1 cleavage products could mitigate obesity-related metabolic dysregulation (Fig. 1). This evidence concerns the gene SPTBN1 and obesity disorder.